In its largest deal to date, Danaher has agreed to buy General Electric’s (GE) biopharmaceutical business, GE Biopharma, for US$21.4 B in cash. The acquisition will establish Danaher as a leading provider of bioprocessing solutions and increase its life sciences business revenue by 46%. For GE, the proceeds from the deal will considerably improve the company’s balance sheet having lost two thirds of its market value in the last two years after a series of operational and investment mishaps.